Blar i Department of Clinical Medicine på forfatter "Straume, Oddbjørn"
-
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
Krüger, Kristi; Silwal-Pandit, Laxmi; Wik, Elisabeth; Straume, Oddbjørn; Stefansson, Ingunn Marie; Borgen, Elin; Garred, Øystein; Naume, Bjørn; Engebråten, Olav; Akslen, Lars Andreas (Journal article; Peer reviewed, 2021)A subset of breast cancer patients benefits from preoperative bevacizumab and chemotherapy, but validated predictive biomarkers are lacking. Here, we aimed to evaluate tissue-based angiogenesis markers for potential ... -
Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
Pilskog, Martin; Nilsen, Gry Hilde; Beisland, Christian; Straume, Oddbjørn (Peer reviewed; Journal article, 2019)Introduction: Clear cell renal cell carcinoma (ccRCC) is the most common type among renal cell carcinomas, and anti-angiogenic treatment is currently first line therapy in metastatic ccRCC (mccRCC). Response rates and ... -
Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report
Tzoulis, Charalampos; Schwarzlmüller, Thomas; Søfteland, Eirik; Neckelmann, Gesche; Biermann, Martin; Haroche, Julien; Straume, Oddbjørn; Gjerde, Ivar Otto; Vintermyr, Olav Karsten (Peer reviewed; Journal article, 2015-04-30)Background: Erdheim-Chester disease is a rare histiocytosis characterized by multi-systemic organ involvement. Immune-modulating agents such as interferon-alpha have limited success and the disorder is progressive and ... -
Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study
Schuster, Cornelia; Akslen, Lars A.; Straume, Oddbjørn (Journal article, 2016-05-11)The aim of this study was to identify potential predictive biomarkers in 35 patients with metastatic melanoma treated with anti-angiogenic bevacizumab monotherapy in a clinical phase II study. The immunohistochemical ... -
HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?
Seo, Mikyung Kelly; Straume, Oddbjørn; Akslen, Lars A.; Cairns, John Alexander (Journal article; Peer reviewed, 2020)Background: Despite the extensive use of bevacizumab in a range of oncology indications, the US FDA revoked its approval for breast cancers, and multiple negative trials in several solid malignancies have been reported, ... -
Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma
Ladstein, Rita Grude; Bachmann, Ingeborg M.; Straume, Oddbjørn; Akslen, Lars A. (Peer reviewed; Journal article, 2010-04-14)Background: Tumor cell proliferation is a predictor of survival in cutaneous melanoma. The aim of the present study was to evaluate the prognostic impact of mitotic count, Ki-67 expression and novel proliferation markers ... -
Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy
Schuster, Cornelia; Akslen, Lars A.; Stokowy, Tomasz; Straume, Oddbjørn (Peer reviewed; Journal article, 2019)The incidence of malignant melanoma is rising worldwide and survival for metastatic disease is still poor. Recently, new treatment options have become available. Still, predictive biomarkers are needed to optimise treatment ... -
Tumor necrosis is associated with increased alphav beta3 integrin expression and poor prognosis in nodular cutaneous melanomas
Bachmann, Ingeborg M.; Ladstein, Rita Grude; Straume, Oddbjørn; Naumov, George N.; Akslen, Lars A. (Peer reviewed; Journal article, 2008-12-05)Background: Tumor necrosis and apoptotic activity are considered important in cancer progression, but these features have not been much studied in melanomas. Our hypothesis was that rapid growth in cutaneous melanomas of ...